Cancer treatment compounds

By designing novel betamethasone derivatives, the problems of narrow therapeutic index and severe side effects of existing betamethasone drugs in cancer treatment have been solved. This approach achieves selective activation of tumors and reduces side effects, while improving cancer cell toxicity, demonstrating significant anticancer activity and safety.

CN120917013APending Publication Date: 2025-11-07UNIVERSITY OF BRADFORD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202480017538.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-01-17
Filing Date
2024-01-17
Publication Date
2025-11-07

Smart Images

  • Figure CN120917013A_ABST
    Figure CN120917013A_ABST
Patent Text Reader

Abstract

The present invention relates to a group of compounds generally belonging to the class of compounds referred to as ducarmycin. The invention provides a group of novel duocarmycin with a structure conforming to a formula I. The invention further provides a preparation method of the duocarmycin. The compound has the effect of treating cancers.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Materials and methods relating to linkers for use in protein drug conjugates

    US20170232108A1

  • Monomethylvaline compounds capable of conjugation to ligands

    US7964566B2